Sanofi withdraws Campath in US and EU Pharma Times French drugmaker Sanofi's Genzyme unit is pulling its cancer drug Campath/MabCampath from markets on both sides of the Atlantic in order to optimise the pending launch of the drug as a treatment for multiple sclerosis, according to reports. The company ... See all stories on this topic »